Case study

Faron Pharmaceuticals

Leukaemia is one of the deadliest cancers, so promising trial results are big news. Faron Pharmaceuticals' Phase 2 results for Bexmarilimab, presented for the first time at the European Haematology Association Congress, showed that combined with azacitidine it more than doubled median survival rates, with particular promise for patients with relapsed or hard-to-treat blood cancers. We built a broadcast PR campaign around the results, putting Faron's CEO on air in radio and TV interviews as an expert in developing new cancer therapies. The campaign secured 15 items of radio and TV coverage reaching 6.2 million, including Sky News TV, BBC Radio Manchester, BBC Radio Cornwall and LBC News.

15Items of coverage
6.2 millionCombined reach
1h 22mTime on air

Coverage highlights

Watch the coverage

Sky News

Campaign video

The story

Faron Pharmaceuticals

The campaign
Phase 2 Trial Results
The aim
The campaign aimed to position Faron as a leading innovator in immunotherapy and raise awareness of its pioneering work in clinical cancer research. It sought to establish the company’s CEO as a recognised expert in therapeutic treatments, highlighting his leadership in developing novel, life-saving cancer therapies. The campaign focused on showcasing Faron’s commitment to tackling leukaemia, one of the deadliest cancers, through groundbreaking research. A key milestone was the release of the promising Phase 2 trial results for Bexmarilimab (Bex), especially in patients with relapsed or hard-to-treat blood cancers. When combined with azacitidine, bex more than doubled median survival rates. These results were presented for the first time at the European Haematology Association Congress.
The result
15 items of coverage reaching 6.2 million, including Sky News TV, BBC Radio Manchester, BBC Radio Cornwall, Sky News Radio.

Planning a broadcast PR campaign?

Talk to the team about radio and TV interviews for your brand, or for your clients if you run a PR agency.

Book a call with the team